JP2023543439A5 - - Google Patents

Info

Publication number
JP2023543439A5
JP2023543439A5 JP2023518416A JP2023518416A JP2023543439A5 JP 2023543439 A5 JP2023543439 A5 JP 2023543439A5 JP 2023518416 A JP2023518416 A JP 2023518416A JP 2023518416 A JP2023518416 A JP 2023518416A JP 2023543439 A5 JP2023543439 A5 JP 2023543439A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
human patient
compound
muscular dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051274 external-priority patent/WO2022061287A1/en
Publication of JP2023543439A publication Critical patent/JP2023543439A/ja
Publication of JP2023543439A5 publication Critical patent/JP2023543439A5/ja
Pending legal-status Critical Current

Links

JP2023518416A 2020-09-21 2021-09-21 NF-κB媒介疾患の処置 Pending JP2023543439A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063081073P 2020-09-21 2020-09-21
US63/081,073 2020-09-21
US202163195473P 2021-06-01 2021-06-01
US63/195,473 2021-06-01
US202163214908P 2021-06-25 2021-06-25
US63/214,908 2021-06-25
PCT/US2021/051274 WO2022061287A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Publications (2)

Publication Number Publication Date
JP2023543439A JP2023543439A (ja) 2023-10-16
JP2023543439A5 true JP2023543439A5 (cg-RX-API-DMAC10.html) 2024-10-01

Family

ID=80776432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518416A Pending JP2023543439A (ja) 2020-09-21 2021-09-21 NF-κB媒介疾患の処置

Country Status (9)

Country Link
US (2) US20220184098A1 (cg-RX-API-DMAC10.html)
EP (1) EP4213855A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543439A (cg-RX-API-DMAC10.html)
KR (1) KR20230092905A (cg-RX-API-DMAC10.html)
AU (1) AU2021343534A1 (cg-RX-API-DMAC10.html)
CA (1) CA3170698A1 (cg-RX-API-DMAC10.html)
IL (1) IL301500A (cg-RX-API-DMAC10.html)
MX (1) MX2023003258A (cg-RX-API-DMAC10.html)
WO (1) WO2022061287A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436583A4 (en) * 2021-11-22 2025-04-02 ReveraGen BioPharma, Inc. TREATMENT OF NF-kB-MEDIATED DISEASE
WO2025199347A1 (en) * 2024-03-21 2025-09-25 Reveragen Biopharma, Inc. Treatment of glomerulonephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279325B2 (en) * 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP2785351A4 (en) * 2011-11-29 2015-05-27 Reveragen Biopharma Inc NONTHORMONAL STEROID MODULATORS OF NF-KB FOR THE TREATMENT OF DISEASES
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
US11382922B2 (en) * 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Similar Documents

Publication Publication Date Title
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
NORRIS et al. The administration of guanidine in amyotrophic lateral sclerosis
JP6768733B2 (ja) モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP7153950B2 (ja) 神経発達障害療法
LaForce et al. Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study
Gross et al. The longterm treatment of an asthmatic patient using phentolamine
EP3137622B1 (en) Methods of reducing decline in vital capacity
JP2020002150A (ja) 15−hepeを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法
Rollinson et al. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate
EP3395341B1 (en) Composition for treating motor neuron diseases and use thereof
JPH09323927A (ja) 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤
WO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
CN117597131A (zh) 包含牛磺脱氧胆酸或其药学上可接受的盐作为有效成分的新型冠状病毒肺炎治疗用组合物
JP2023541007A5 (cg-RX-API-DMAC10.html)
Hollow et al. Autonomic manifestations of tetanus
DE69106008T2 (de) Behandlung von Schlaf-Apnoea mit Azapironderivaten.
RU2834426C2 (ru) Способ лечения вирусных инфекций и композиция для его осуществления
JP6864964B2 (ja) 経口睡眠改善剤
Meade et al. Neuropathy after thalidomide (“Distaval”)
US11364218B2 (en) Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome
Mosannen et al. Fibrodysplasia Ossificans Progressiva (FOP): A Case Report with Oral and Maxillofacial Manifestations and new radiographic feature
Holyfield et al. Effect of a prescription digital therapeutic for chronic insomnia on daytime sleepiness: Results from the real-world DREAM study
WO2025249254A1 (ja) 血球貪食症候群治療剤及びその使用
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
JP6414727B2 (ja) 関節疾患の治療予防剤